title: Conjunctivitis caused by Neisseria gonorrhoeae isolates with reduced cephalosporin susceptibility and multidrug resistance.
abstract: We report two cases of conjunctivitis caused by Neisseria gonorrhoeae with reduced cephalosporin susceptibility. Patients showed no response to cefmenoxime eye drops and intravenous ceftriaxone administration. The patients' condition improved after the addition of oral minocycline. The isolates contained the mosaic penA for reduction of β-lactam susceptibility.
authors.affiliation: Department of Ophthalmology, Ehime University, Graduate School of Medicine, Shitsukawa, Toon, Ehime, Japan.
authors.forename: Takashi
authors.initials: T
authors.lastname: Suzuki
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Kitagawa
authors.forename: Yosuke
authors.initials: Y
authors.lastname: Maruyama
authors.forename: Satoshi
authors.initials: S
authors.lastname: Yamaguchi
authors.forename: Yuri
authors.initials: Y
authors.lastname: Sakane
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Miyamoto
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Ohashi
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002511:Cephalosporins / Q000494:pharmacology* / Q000627:therapeutic use; D003231:Conjunctivitis / Q000382:microbiology*; D024901:Drug Resistance, Multiple, Bacterial; D005260:Female; D005798:Genes, Bacterial; D006069:Gonorrhea / Q000382:microbiology*; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D008911:Minocycline / Q000627:therapeutic use; D009344:Neisseria gonorrhoeae / Q000187:drug effects* / Q000302:isolation & purification*; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D008911:Minocycline
references.citation: J Clin Microbiol. 2000 Feb;38(2):521-5
references.pmid: 10655338
references.citation: Eye (Lond). 2009 Feb;23(2):339-44
references.pmid: 18064057
references.citation: Antimicrob Agents Chemother. 2012 Nov;56(11):5633-41
references.pmid: 22908152
references.citation: Ophthalmology. 1987 May;94(5):525-31
references.pmid: 3601368
references.citation: Antimicrob Agents Chemother. 2009 Sep;53(9):4032-4
references.pmid: 19546370
references.citation: Int J Antimicrob Agents. 2006 Jan;27(1):20-6
references.pmid: 16318912
references.citation: Antimicrob Agents Chemother. 2002 Mar;46(3):769-77
references.pmid: 11850260
references.citation: Am J Ophthalmol. 2012 Dec;154(6):949-957.e1
references.pmid: 22967863
references.citation: Antimicrob Agents Chemother. 2011 Jul;55(7):3538-45
references.pmid: 21576437
references.citation: Antimicrob Agents Chemother. 2010 Mar;54(3):1060-7
references.pmid: 20028823
references.citation: Future Microbiol. 2012 Dec;7(12):1401-22
references.pmid: 23231489
references.citation: Surv Ophthalmol. 1987 Nov-Dec;32(3):199-208
references.pmid: 2965423
references.citation: JAMA. 2013 Jan 9;309(2):163-70
references.pmid: 23299608
references.citation: Antimicrob Agents Chemother. 2001 Sep;45(9):2651-4
references.pmid: 11502546
references.citation: Emerg Infect Dis. 2011 Jan;17(1):148-9
references.pmid: 21192886
references.citation: Am J Ophthalmol. 1986 Nov 15;102(5):575-83
references.pmid: 3777076
references.citation: J Ocul Pharmacol Ther. 2009 Apr;25(2):133-9
references.pmid: 19284320
references.citation: J Clin Microbiol. 1994 Jun;32(6):1586-8
references.pmid: 8077409
references.citation: Arch Ophthalmol. 1989 Jan;107(1):93-5
references.pmid: 2910292